Joe Albanese is Owner and Managing Director of Albanese Consulting LLC, which he formed after more than 29 years of experience in the pharmaceutical industry. He recently retired from Janssen Pharmaceuticals (part of Johnson & Johnson), where he held positions in R&D, Supply Chain, and Quality in both Small Molecule and Biotherapeutics development and manufacturing. As part of his duties, he was responsible for the compendial vigilance process for all Janssen products ensuring compliance with all major global and national pharmacopoeias. He actively served in industry working groups such as the PhRMA Limited Duration Key Issues Team for compendial issues with USP, the EFPIA Biotherapeutics subteam for the elaboration of biotherapeutic compendial standards, and was a member of the USP General Notices Project Team. He is currently active in the industry trade organizations NJPQCA, Midwest Compendial Discussion group and PDA that influence global health and compendial authorities. He recently co-authored a comprehensive 12-part series of articles, with J. Mark Wiggins, on compendial compliance that were published in Pharmaceutical Technology and BioPharm International.
